Viewing Study NCT06984718


Ignite Creation Date: 2025-12-25 @ 4:35 AM
Ignite Modification Date: 2026-03-09 @ 11:22 AM
Study NCT ID: NCT06984718
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-05-22
First Post: 2025-05-15
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC
Sponsor: Akeso
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None HCC View
None Hepatocellular Carcinoma View
Keywords: